Xponance Inc. Acquires Shares of 8,534 Guardant Health, Inc. (NASDAQ:GH)

Xponance Inc. bought a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 8,534 shares of the company's stock, valued at approximately $261,000.

• 4 Healthcare Stocks With Massive Gains—and More to Come

Several other hedge funds also recently made changes to their positions in the company. R Squared Ltd bought a new position in Guardant Health during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman & Baird LLC bought a new position in shares of Guardant Health during the fourth quarter valued at approximately $58,000. Jones Financial Companies Lllp lifted its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after acquiring an additional 817 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after acquiring an additional 929 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $43.14 on Friday. The stock has a market cap of $5.32 billion, a price-to-earnings ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The firm's 50-day moving average is $44.66 and its 200 day moving average is $34.24.

• Deciphering Disruption: Inside Cathie Wood's Latest Plays

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GH. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Morgan Stanley increased their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Stifel Nicolaus upped their target price on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, The Goldman Sachs Group raised their target price on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has an average rating of "Buy" and an average target price of $48.95.

• 3 Fast-Growing Stocks Analysts See Doubling in Price

Check Out Our Latest Stock Analysis on Guardant Health

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

• Five stocks we like better than Guardant Health
• Comparing and Trading High PE Ratio Stocks
• Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
• Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
• JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?
• What is a buyback in stocks? A comprehensive guide for investors
• Buy the Chewy Stock Reversal? Here’s Why Now Is the Time

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Guardant Health Right Now?

Before you consider Guardant Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.

While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here